Part 2: Therapeutic Strategies in Motion
While COVID-19 may be here to stay, there is hope. That’s because scientists have been studying severe acute respiratory syndrome (SARS) since an outbreak in China in 2003 — and the coronavirus ravaging the globe today, SARS-CoV-2, is an offspring of that 2003 virus. In this chapter, Dr. Patrick Soon-Shiong, the executive chairman of the Los Angeles Times, examines treatments scientists are contemplating as they take up the fight against COVID-19.
Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious diseases. He is also the chairman and chief executive of NantWorks and the owner of or investor in a number of companies, including ImmunityBio and NantKwest, which are currently researching immunotherapies for COVID-19.
Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious diseases. He is also the chairman and chief executive of NantWorks and the owner of or investor in a number of companies, including ImmunityBio and NantKwest, which are currently researching immunotherapies for COVID-19.
